Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

NCT02414269 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

113

Enrollment

OTHER

Sponsor class

Conditions

Malignant Pleural Disease
Mesothelioma
Metastases
Lung Cancer
Breast Cancer

Interventions

GENETIC: iCasp9M28z T cell infusions
DRUG: cyclophosphamide
DRUG: pembrolizumab

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]